Reuters logo
3 个月内
BRIEF-Roche receives FDA approval for complementary pd-l1 biomarker test in Urothelial Carcinoma
2017年5月2日 / 晚上10点28分 / 3 个月内

BRIEF-Roche receives FDA approval for complementary pd-l1 biomarker test in Urothelial Carcinoma

1 分钟阅读

May 2 (Reuters) - Roche Holding Ag

* Roche receives FDA approval for Complementary PD-l1 (SP263) Biomarker test in Urothelial carcinoma

* Continues to pursue regulatory approval for Ventana PD-l1 assay in other cancer indications in US and in other geographies Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below